Safety Profile of COVID-19 Vaccination among Adolescents in India - An Initial Experience
Introduction: The government of India announced a nationwide mass vaccination drive for adolescents 15-17 years of age from 3rd January 2022. This announcement was considered a welcome measure by
public health experts to increase vaccination coverage throughout the nation. This study was undertaken to understand the safety profile of COVID-19 vaccination among initial adolescent recipients.
Methodology: The first 500 such beneficiaries (adolescents of age 15-18 years) who received COVAXIN were identified. All the vaccination beneficiaries were prospectively taken in the study. These children were telephonically called and assessed for AEFI occurring up to 2 weeks.
Results: Among the first 500 beneficiaries vaccinated over the first week of the vaccination drive, 68 (only 13.6%) subjects developed an AEFI. These AEFI were all after the first dose of the vaccine.
Conclusion: Our initial experience is that COVAXIN is a relatively safe vaccine in adolescents with the majority of AEFI being mild. It is necessary for documentation and knowledge of the AEFI profile as this will help decrease vaccine hesitancy and promote acceptance.
How to cite this article:
Tiwari P, Kumar A, Kishore J, Saxena A, Ish P, Nath R. Safety Profile of COVID-19 Vaccination among
Adolescents in India - An Initial Experience. Epidem Int. 2022;7(2):13-16.
Srivastava RK, Ish P, Covid-Vaccination Group S. The initial experience of COVID-19 vaccination from a
tertiary care centre of India. Monaldi Arch Chest Dis. 2021 Mar;91(4). [PubMed] [Google Scholar]
Vadrevu KM, Reddy S, Jogdand H, Ganneru B, Mirza N, Tripathy VN, Singh C, Khalatkar V, Prasanth S, Rai S, Ella
R, Blackwelder W, Prasad S, Ella K. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (BBV152) in children from 2 to 18 years of age: an open-label, age-de-escalation phase 2/3 study. Lancet Infect Dis. 2022 Sep;22(9):1303-12. [PubMed] [Google Scholar]
Covaxin receives approval for emergency use in 12-18 years old children. Available from: https://www.
livemint.com/science/health/covaxin-receivesapproval-for-emergency-use-in-12-18-years-oldchildren11640480429321.html. Last accessed on 18 Jan 2022.
Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, Ding B, Dooley J, Girard B, Hillebrand W, Pajon R, Miller JM, Leav B, McPhee R. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in escents. N Engl J Med. 2021 Dec;385(24):2241-51. [PubMed] [Google Scholar]
Kwan MYW, Chua GT, Chow CB, Tsao SSL, To KKW, Yuen KY, Lau YL, Ip P. mRNA COVID vaccine and myocarditis
in adolescents. Hong Kong Med J. 2021 Oct;27(5):326-7. [PubMed] [Google Scholar]
Luxi N, Giovanazzi A, Capuano A, Crisafulli S, Cutroneo PM, Fantini MP, Ferrajolo C, Moretti U, Poluzzi E,
Raschi E, Ravaldi C, Reno C, Tuccori M, Vannacci A, Zanoni G, Trifirò G; Ilmiovaccino COVID19 collaborating
group. COVID-19 vaccination in pregnancy, paediatrics, immunocompromised patients and persons with history
of allergy or prior SARS-CoV-2 Infection: Overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety. Drug Saf. 2021 Dec;44(12):1247-69. [PubMed] [Google Scholar]
WHO Classification of AEFIS. Accessed: 22 February 2021. Available from: https://vaccine-safety-training. org/classification-of-aefis.html. Last accessed on 18 Jan 2022.
Gupta S, Malhotra N, Gupta N, Agrawal S, Ish P. The curious case of coronavirus disease 2019 (COVID-19)
in children. J Pediatr. 2020 Jul;222:258-9. [PubMed] [Google Scholar]
Iyengar KP, Nune A, Ish P, Botchu R, Shashidhara MK, Jain VK. Multisystem inflammatory syndrome after SARSCoV-2 vaccination (MIS-V), to interpret with caution. Postgrad Med J. 2021 Aug;postgradmedj-2021-140869. [PubMed] [Google Scholar]
Chen M, Yuan Y, Zhou Y, Deng Z, Zhao J, Feng F, Zou H, Sun C. Safety of SARS-CoV-2 vaccines: a systematic
review and meta-analysis of randomized controlled trials. Infect Dis Poverty. 2021 Jul;10(1):94. [PubMed] [Google Scholar]
Kunal S, Aditi, Gupta K, Ish P. COVID-19 variants in India: Potential role in second wave and impact on
vaccination. Heart Lung. 2021 Nov-Dec;50(6):784-7. [PubMed] [Google Scholar]
Iyengar KP, Singh B, Vaishya R, Jain VK, Ish P. Should COVID-19 vaccination be made mandatory? Lung India.
Jul-Aug;38(4):379-81. [PubMed] [Google Scholar]
Copyright (c) 2022 Poornima Tiwari, Amit Kumar, Jugal Kishore, Anirudh Saxena, Pranav Ish, Ravindra Nath, SJH Adolescent Vaccination Working Group Nath
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.